Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05351281
Other study ID # NL7830507821
Secondary ID MEC-2021-0624
Status Recruiting
Phase N/A
First received
Last updated
Start date April 29, 2022
Est. completion date August 2024

Study information

Verified date February 2024
Source Erasmus Medical Center
Contact Marte van Hylckama Vlieg, MD
Phone +31648857686
Email m.vanhylckamavlieg@erasmusmc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The AMUSE trial is a multicentre stepped-wedge cluster randomized controlled trial where medication optimization of patients with a life expectancy of less than three months is investigated by using CDSS-OPTIMED (a personalized medication advice to attending physicians of patients in the last phase of life) The investigators will include 250 patients, in 7 different study sites across the Netherlands. The primary outcome is an assessment of the quality of life of patients, two weeks after baseline assessment.


Description:

Rationale: patients in the last phase of life often use many medications that are continued until shortly before they die. This is partly inevitable, because these patients often experience multiple distressing symptoms. However, for a considerable number of medications currently often used at the end of life, the benefit is debatable, e.g. because they are aimed at the long-term prevention of illness. Primary objective: to examine whether the use of CDSS-OPTIMED, a personalized medication advice to attending physicians of patients in the last phase of life, contributes to patients' quality of life. Main study endpoints: the primary endpoint is patients' quality of life two weeks after baseline assessment, as measured by the EORTC QLQ-C15-PAL questionnaire (scale 0 to 100). Potential risks and benefits associated with participation: the intervention in this trial supports physicians in using available evidence and knowledge when deprescribing medication for patients in the last phase of life. The intervention does not involve experimental treatment or medication. The investigators expect no other risks than known side effects of (stopping) medications. The investigators are aware that the trial population concerns vulnerable people who may experience fluctuating symptoms and levels of suffering across their disease trajectory. The investigators acknowledge the risk of overburdening participants. If patients feel burdened by participating in the study, they are encouraged to indicate that.


Recruitment information / eligibility

Status Recruiting
Enrollment 250
Est. completion date August 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient is 18 years or older and provides informed consent to participate. - The patient is aware that recovering from his/her disease is unlikely, to be assessed by the attending physician. - The patient is competent to decide about trial participation - The patient has a life expectancy of at least two weeks and at most three months, as estimated by an attending physician. Exclusion Criteria: - The patient is incapable of filling in a questionnaire (patients may be supported by relatives when filling in the questionnaire).

Study Design


Intervention

Device:
CDSS-OPTIMED
The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient with a life expectancy of less than 3 months.

Locations

Country Name City State
Netherlands Noordwest Ziekenhuisgroep Alkmaar
Netherlands Rijnstate Hospital Arnhem
Netherlands Gezondheidscentrum Krimpen Krimpen Aan Den IJssel
Netherlands Nijmegen University Academic Network Family Medicine Nijmegen
Netherlands Erasmus Medical Center Rotterdam
Netherlands Ikazia Hospital Rotterdam
Netherlands Laurens Cadenza Zuid Rotterdam

Sponsors (7)

Lead Sponsor Collaborator
Prof.dr Carin (C.C.D.) van der Rijt Gezondheidscentrum Krimpen, Ikazia Hospital, Rotterdam, Laurens Cadenza Zuid, Nijmegen University Academic Network Family Medicine, Noordwest Ziekenhuisgroep, Rijnstate Hospital

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Costs of the intervention Development and training costs (proformas completed by the developers and the study personnel).
Operational costs (including time spent on discussing medication alerts with the pharmacist and patient/relative derived from patients' medical records. And time registrations via automated system extracts, derived from CDSS-OPTIMED)
Retrospectively over full study period. Full study period is from inclusion until death, with a maximum of 24 weeks.
Primary Patients' quality of life Measured by the quality of life question of the European Organization for Research and Treatment of Cancer Quality of Life Group 15 item core questionnaire for palliative care ( = EORTC QLQ-C15-PAL questionnaire)
Scale 1 to 7. Scale minimum 1 (very poor). Scale maximum 7 (excellent).
Score will be rescaled to a scale from 0 to 100, in which 100 is an excellent outcome
Two weeks after baseline assessment
Secondary Patients' quality of life Measured by the quality of life question of the European Organization for Research and Treatment of Cancer Quality of Life Group 15 item core questionnaire for palliative care ( = EORTC QLQ-C15-PAL questionnaire)
Scale 1 to 7. Scale minimum 1 (very poor). Scale maximum 7 (excellent).
Score will be rescaled to a scale from 0 to 100, in which 100 is an excellent outcome
At day 7, 21, 28, and then every 28 days until death, with a maximum of 24 weeks,
Secondary Symptoms and the occurrence of potential side effects of continuing or discontinuing medication Assessed by the Utrecht Symptoom Dagboek (USD, which is based on the Edmonton Symptom Assessment Scale (ESAS))
Scale 0 to 10. Scale minimum 0 (no symptoms). Scale maximum 10 (worst possible symptoms)
At day 1-7, 14, 21, 28, and then every 28 days until death, with a maximum of 24 weeks
Secondary Systolic and Diastolic Blood Pressure (mmHg) in case of using antihypertensives (continued or discontinued) Measured by patients' attending health care professional At day 1-7, 14, 21, 28, and then every 28 days until death, with a maximum of 24 weeks
Secondary Glucose level (mmol/L) in case of using antidiabetics (continued or discontinued) Measured by patients' attending health care professional At day 1-7, 14, 21, 28, and then every 28 days until death, with a maximum of 24 weeks
Secondary Occurence of thrombo-embolic and bleeding events Measured and reported in the data management system by the time between inclusion and death From inclusion until death, with a maximum of 24 weeks
Secondary Time spent on discussing the medication with the patient As registered in the electronic patient files on a time scale (0-5 minutes, 6-10 minutes, 11-15 minutes, 16-20 minutes, >21minutes) Scale minimum: 0-5 minutes (short). Scale maximum: >21 minutes (long) From inclusion until death, with a maximum of 24 weeks
Secondary Health care costs Measured by using a medical file checklist. Items to be assessed include: medication prescriptions, hospital admissions and in-hospital care Retrospectively over full study period (From inclusion until death, with a maximum of 24 weeks)
Secondary Medication prescriptions (All medication used by the patient during te whole study period) Measured by using a medical file checklist in our data management system. Derived from patients' medical records and the pharmacist's information system From inclusion until death, with a maximum of 24 weeks
Secondary Patient survival Derived from patients' medical records and contact with the patient From inclusion until death, with a maximum of 24 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Completed NCT06238557 - Prospective Evaluation of Psychological Consequences and Impact on Long-term Quality of Life
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT05472935 - Asynchronous Mindfulness Based Stress Reduction to Reduce Burnout in Licensed Clinical Social Workers N/A
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery
Completed NCT04281953 - Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
Recruiting NCT05546931 - Mobile Health Program for Rural Hypertension N/A
Active, not recruiting NCT04746664 - Effects of Nutrition Counselling on Old Age People's Nutritional Status and Quality of Life in Bahir Dar City, North West Ethiopia N/A
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Recruiting NCT04142827 - The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX) N/A
Active, not recruiting NCT05903638 - A Pilot RCT: the Impact of a Virtual MBSR Course on Women With Primary Infertility N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Completed NCT06216015 - Exercise Training and Kidney Transplantation N/A
Completed NCT03813420 - Sleep Quality of Physiotherapy Students Quality of Life and Physical Activity Level N/A
Recruiting NCT05550545 - Infant RSV Infections and Health-related Quality of Life of Families
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Recruiting NCT05233020 - Robotic Versus Hybrid Assisted Ventral Hernia Repair N/A
Terminated NCT03304184 - The Role of Biodentine in Class V Dental Lesions on Oral Health Related Quality of Life Phase 3
Completed NCT05063305 - Probiotics, Immunity, Stress, and QofL N/A
Recruiting NCT05380856 - Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction N/A